CD3D

Across TCGA pan-cancer cohorts, CD3D Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD3D data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher CD3D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD3D expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THCA, SKCM, and ACC are the cancer types where CD3D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.098	0.941	<.001	42	view →
SKCM	DFS	Median	III,IV	0.920	0.462	.021	11	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
COAD	OS	Median	All	0.556	0.870	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD3D–THCA (OS)

Open the THCA breakdown →